PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.65%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
44.07%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
473.10%
Other expenses growth above 20% signals concerning cost expansion. Seth Klarman would scrutinize unusual items.
6.92%
Operating expenses growth 5-10% suggests significant expansion. Howard Marks would investigate necessity.
6.92%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
473.10%
D&A growth above 10% signals heavy asset expansion. Seth Klarman would demand evidence of future payoff.
73.55%
EBITDA growth above 15% demonstrates exceptional operating performance. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-6.92%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
163.21%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
121.05%
Pre-tax income growth above 15% demonstrates exceptional profitability improvement. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Net income growth above 15% demonstrates exceptional bottom-line expansion. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
121.15%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
115.11%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
2.25%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
42.15%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.